Eiger snaps up $7.1M to treat hepatitis
Eiger BioPharmaceuticals, developer of treatments for strains of hepatitis, announced that it brought in $7.1 million in first-round funding from InterWest Partners and Vivo Ventures. The Palo Alto, Calif. company will use the new money to push its lead compound — which targets hepatitis C… Continue Reading
Nora Pharma reels in $25M for women’s health
Nora Pharmaceuticals, developer of women’s reproductive health drugs and devices, brought in $25 million in first round financing from Burrill & Co., Prospect Venture Partners and Vivo Ventures. The San Francisco-based company is still pretty stealthy (it doesn’t even have a website). It did release… Continue Reading
New $32M round helps APT battle lung transplant rejection
APT Pharmaceuticals Inc. announced today that it has raised $32 million in its second round from a flock of investors led by Three Arch Partners, and including InterWest Partners, Pinnacle Ventures, Charter Life Sciences, Great Point Partners, Versant Ventures and Vivo Ventures.
APT, headquartered in Burlingame,… Continue Reading
InterKrin raises $18.5M for continued work on diabetes drug
Palo Alto, Calif.-based InterKrin is developing an anti-diabetes drug. It has raised an $18.5 million in a not-yet-closed third round of funding, according to VentureWire. The round was led by Amgen and Skyline Ventures and joined by existing backers Sofinnova Ventures, OrbiMed Advisors, Asset Management,… Continue Reading
Tria Beauty raises $30M to remove your excess back hair
Tria Beauty (formerly known as SpectraGenics), the Pleasanton, Calif. maker of a device that uses lasers for hair removal, has raised $30 million in its fifth round of financing.
Unlike similar devices, Tria’s hair removal system has been cleared for home use. While it has been… Continue Reading
Capnia, a CO2-through-nose treatment company, raises $16.3M
Capnia, a Palo Alto, Calif., company that delivers carbon dioxide through a patient’s nose to treat things like migraines and rhinitis, has raised $16.3 million of a potential $19 million third round of funding.
Backers include existing investors Vivo Ventures, Asset Management and Teknoinvest, as well… Continue Reading
Life sciences briefing: Wednesday, Dec. 12, 2007
TODAY’S HEADLINES:
Topical Botox maker Revance gets $43M, option to be acquired by Medicis (release)
Reva Medical draws $42M for resorbable stents (release)
AccentCare raises $8M for senior home-care services (VentureWire, sub req’d)
Light Dimensions aims for $6M for light-based skin treatment (VW)
Carigent pulls in $2M for nanoparticle drugs… Continue Reading
Life sciences briefing: Monday, Nov. 26, 2007
Featured companies: Biospace Med, Carbylan BioSurgery, GVK BioSciences, IntraSafe Medical, InViragen, Medingo, ParadigmHealth, Precimed, SV Life Sciences
UPDATED: Expanded items on Carbylan, Medingo, and GVK Biosciences.
Carbylan raises $20M for arthritis, sinusitis drug implants — Palo Alto, Calif.-based Carbylan BioSurgery, a medical-device maker focused on polymer-based drug-delivery technologies, raised… Continue Reading
Life sciences briefing: Thursday, Oct. 4, 2007
Featured companies: 23andMe, APT Pharmaceuticals, Hyperion Therapeutics, Isis Biopolymer, Virogenomics
UPDATED at 10:30am PT.
APT Pharma raises $22M for transplant and heart drugs — Burlingame, Calif.’s APT Pharmaceuticals, a specialty pharma currently focused on a drug to fight organ-transplant rejection, raised $22 million in an extension of its first… Continue Reading
Life sciences briefing: Friday, Sept. 28, 2007
Featured companies: Imalux, Sagent Pharmaceuticals, Sequel Pharmaceuticals, Sinexus, TranS1, U.S. Spinal Technologies
Sagent Pharmaceuticals draws in $53M for injectable generics — Sagent Pharmaceuticals, proving that there’s still life in the apparently lucrative but boring specialty-pharmaceuticals business, raised $53 million in a first funding round. Vivo Ventures led… Continue Reading
Life sciences briefing: Monday, Aug. 27, 2007
Featured companies: Bravo Health, InfraReDx, MedAssets, Prestwick Pharmaceuticals
Prestwick Pharma raises $20M for neuro drugs — Specialty pharma Prestwick Pharmaceuticals, a Washington, D.C., firm that acquires cast-off drug candidates to treat neurological conditions, raised $20 million from existing investors, VentureWire reports (subscription required). Among those participating in… Continue Reading
Vivo Ventures aims for Asia investment with $275M fund
Vivo Ventures plans its first in Asian life-science investments now that it has closed a new fund, VentureWire is reporting (subscription required). The Palo Alto, Calif., outfit, formerly known as BioAsia Investments due to its former association with Asian investors, just closed a $275 million… Continue Reading
Insomnia drug company, TransOral, raises $40M more
TransOral Pharmaceuticals, a Pt. Richmond, Calif. developer of a drug that treats insomnia, has raised $40 million in a fourth round of funding.
See the company’s announcement here.
The investor syndicate was led by New Enterprise Associates (NEA) and included follow-on investments by New Leaf Venture… Continue Reading
InteKrin, a co. that fights diabetes and obesity, raises $23M
InteKrin Therapeutics, Inc., a Palo Alto company developing products to counter diabetes, metabolism and obesity, said it has raised $23 million in venture financing.
The financing was led by Sofinnova Ventures and included Orbimed Advisors and Vivo Ventures, as well as earlier investors Asset Management… Continue Reading